Blue Sky Health Sector Stock Volatility Report

Notable Movers & Volatility

The dispersion here is extreme: TEM's +41.77% swing ($57.72 → $81.83) and KPTI's -42.06% collapse ($2.14 → $1.24) bracket an 84-point spread in a single sector's tape. TEM was also the cleanest case of underpriced risk — realized/implied of 5.21x with 71.34% realized against 68.48% implied — and it closed at 83.49% of its range, near the top. EBS (+35.58%, closed 85.41%) and MRNA (+24.22%, 78.71% realized vs. 57.80% implied, 2.83x) tell a similar story: options were not paying for the move that arrived.

The reverse held in the deep-IV small caps. CDXS carried 271.88% implied against 50.73% realized (0.37x), ADMA 0.56x, ANAB 0.60x, ADUS 0.72x, QURE 0.77x — expensive protection relative to what actually happened, even where prices fell hard.

Closing location skews bearish among the large caps: BNTX finished at 3.46% of its range, CVS 6.57%, SYK 12.07%, UNH 12.93%, ABT 13.52%, BMY 13.92%. ABBV is the outlier, down 7.54% on the period but closing at 84.48%. KPTI, despite the largest drawdown, ended with a 0.00% period return — a full round trip.

Broader Market Context

Differential behavior within the sector. These 32 names did not trade as a bloc. Managed care (UNH -8.39%, HUM -9.51%, CVS -10.51%, CI +6.83%, CNC +12.65%, ELV +9.31%) split sharply, with the smaller insurers rallying while UNH and CVS bled to the bottom of their ranges — an unusual intra-industry divergence that is more consistent with re-rating within the payor group than with a uniform sector view. Large-cap pharma clustered in a narrow -7% to -12% band (JNJ, ABBV, BMY, MRK, LLY) with realized vol between 17% and 23%, while devices (SYK -19.91%, ABT -14.04%) and small-cap biotech/tools (CDXS, KPTI, DBVT, QURE, all -19% to -42%) carried multiples of that volatility. The sector ETF proxy, XLV, fell only 6.09% with 14.07% realized vol — the calmest line in the report, and a reminder that index-level calm masked severe single-name dispersion.

Rotation vs. idiosyncratic. The broad-based weakness in mega-cap pharma and devices, paired with XLV's decline, is consistent with money rotating *out* of healthcare — the kind of pattern seen when risk appetite improves elsewhere and defensives are funded as a source. But the picture is not clean: TEM, EBS, MRNA and CNC posting strong gains alongside those declines argues that much of the extreme movement was stock-specific. Sub-2x realized/implied ratios in several small caps also suggest positioning was already defensive there, not newly repriced.

Plausible current drivers. Without asserting specific events, the volatility profile is compatible with several live sector themes:

• Ongoing policy uncertainty around drug pricing, reimbursement and coverage rules, which disproportionately hits payors and large-cap pharma — plausibly relevant to the UNH/CVS/HUM weakness and the payor dispersion.
• Clinical, regulatory or data catalysts in biotech, where binary outcomes produce exactly the TEM/KPTI-style tails and the elevated implied vols (100%+) seen in CDXS, KPTI, QURE, DBVT and STIM.
• Rate and growth expectations, which affect long-duration, pre-revenue biotech far more than cash-generative large caps — consistent with the wide gap between the pharma cluster and the small-cap cohort.
• Recurring M&A and partnership speculation in mid-cap biotech, which can sustain elevated implied vol even when realized movement stays modest.